Vanguard Group’s PharMerica Corporation PMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-1,733,958
| Closed | -$50.8M | – | 4104 |
|
|
2017
Q3 | $50.8M | Buy |
1,733,958
+84,254
| +5% | +$2.36M | ﹤0.01% | 2036 |
|
|
2017
Q2 | $43.3M | Buy |
1,649,704
+85,838
| +5% | +$2.11M | ﹤0.01% | 2081 |
|
|
2017
Q1 | $36.6M | Buy |
1,563,866
+29,191
| +2% | +$720K | ﹤0.01% | 2149 |
|
|
2016
Q4 | $38.6M | Sell |
1,534,675
-80,310
| -5% | -$2.03M | ﹤0.01% | 2101 |
|
|
2016
Q3 | $45.3M | Sell |
1,614,985
-4,564
| -0.3% | -$117K | ﹤0.01% | 1973 |
|
|
2016
Q2 | $39.9M | Sell |
1,619,549
-180,832
| -10% | -$4.49M | ﹤0.01% | 2005 |
|
|
2016
Q1 | $39.8M | Buy |
1,800,381
+322,556
| +22% | +$8.58M | ﹤0.01% | 1970 |
|
|
2015
Q4 | $51.7M | Buy |
1,477,825
+223,414
| +18% | +$7M | ﹤0.01% | 1868 |
|
|
2015
Q3 | $35.7M | Sell |
1,254,411
-3,933
| -0.3% | -$132K | ﹤0.01% | 2026 |
|
|
2015
Q2 | $41.9M | Buy |
1,258,344
+22,651
| +2% | +$695K | ﹤0.01% | 2029 |
|
|
2015
Q1 | $34.8M | Sell |
1,235,693
-96,550
| -7% | -$2.4M | ﹤0.01% | 2091 |
|
|
2014
Q4 | $27.6M | Sell |
1,332,243
-21,311
| -2% | -$506K | ﹤0.01% | 2115 |
|
|
2014
Q3 | $33.1M | Buy |
1,353,554
+110,279
| +9% | +$2.92M | ﹤0.01% | 2004 |
|
|
2014
Q2 | $35.5M | Buy |
1,243,275
+95,740
| +8% | +$2.66M | ﹤0.01% | 1994 |
|
|
2014
Q1 | $32.1M | Buy |
1,147,535
+95,398
| +9% | +$2.34M | ﹤0.01% | 2028 |
|
|
2013
Q4 | $22.6M | Buy |
1,052,137
+172,079
| +20% | +$3.13M | ﹤0.01% | 2120 |
|
|
2013
Q3 | $11.7M | Sell |
880,058
-89,629
| -9% | -$1.21M | ﹤0.01% | 2331 |
|
|
2013
Q2 | $13.4M | Buy |
+969,687
| New | +$13.7M | ﹤0.01% | 2207 |
|
Vanguard Group's PMC Position: Q4 2017 in Review
Vanguard Group sold out of PharMerica Corporation (PMC) in Q4 2017, closing a stake of 1,733,958 shares — an estimated $50.8M sold.
Vanguard Group first reported a position in PMC in Q2 2013 and held it in 18 quarters. The position peaked at $51.7M in Q4 2015. 0 funds tracked by Wall St. Rank hold PMC as of Q4 2017.
- Vanguard Group reported no remaining PharMerica Corporation position as of Q4 2017 after selling out during the quarter.
- Vanguard Group sold 1,733,958 PharMerica Corporation shares in Q4 2017, an estimated $50.8M.
- Vanguard Group first reported a position in PharMerica Corporation in Q2 2013 and held it in 18 quarters.
- Vanguard Group's PharMerica Corporation position peaked at $51.7M in Q4 2015.
- 0 funds tracked by Wall St. Rank held PharMerica Corporation as of Q4 2017.
Based on Vanguard Group's 13F filing for Q4 2017, filed 14 Feb 2018.